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What’s already known about this topic? 
• Most eczema trials include the Infants’ Dermatitis Quality of Life Index (IDQoL) or the 
Children’s Dermatology Life Quality Index (CDLQI) as quality of life (QoL) measurement 
instruments 
• It is unclear which instruments are most appropriate to measure QoL in infants, children and 
adolescents with eczema 
What does this study add? 
• Most QoL instruments for infants, children and adolescents with eczema are poorly 
validated, indicating a clear need for further validation work 
Summary 
Background 
Quality of life (QoL) is one of the core outcome domains identified by the Harmonising Outcome 
Measures for Eczema (HOME) initiative to be assessed in every eczema trial. There is uncertainty 
about the most appropriate QoL instrument to measure this domain in infants, children and 
adolescents. 
Objectives 
To systematically evaluate the measurement properties of existing measurement instruments 
developed and/or validated for the measurement of QoL in infants, children and adolescents with 
eczema. 
Methods 
A systematic literature search in PubMed and EMBASE, complemented by a thorough hand search of 
reference lists, retrieved studies on measurement properties of eczema QoL instruments for infants, 
children and adolescents. For all eligible studies, we judged the adequacy of the measurement 
properties and the methodological study quality with the COnsensus-based Standards for the 
selection of health Measurement INstruments (COSMIN) checklist. Results from different studies 
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were summarized in a best evidence synthesis and formed the basis to assign four degrees of 
recommendation.   
Results 
17 articles, 3 of which were found by hand search, were included. These 17 articles reported on 24 
instruments. No instrument can be recommended for use in all eczema trials because none fulfilled 
all required adequacy criteria. With adequate internal consistency, reliability and hypothesis testing, 
the US version of the Childhood Atopic Dermatitis Impact Scale (CADIS), a proxy-reported instrument, 
has the potential to be recommended depending on the results of further validation studies. All 
other instruments, including all self-reported ones, lacked significant validation data.  
Conclusions 
Currently, no QoL instrument for infants, children and adolescents with eczema can be highly 
recommended. Future validation research should primarily focus on the CADIS, but also attempt to 
broaden the evidence base for the validity of self-reported instruments. 
Systematic review registration: CRD42015023483 
Keywords: Core outcome set; eczema; HOME initiative; measurement properties; quality of life 
Introduction 
Affecting more than 10% of infants and children, eczema (synonyms: ‘atopic eczema’, ‘atopic 
dermatitis’) is one of the most common chronic diseases in children in many countries.1-3 A high 
eczema prevalence is also observed in adolescence,2 with a substantial risk of the disease persisting 
into adulthood.4 Despite a multitude of treatment options, evidence-based decision making based on 
systematic reviews and meta-analyses is hampered due to the heterogeneity of outcome 
measurement instruments used, particularly in randomized controlled trials. 
Therefore, the Harmonising Outcome Measures for Eczema (HOME) initiative 
(www.homeforeczema.org) aims to develop a core outcome set (COS) for use in all future eczema 
trials. A COS is a minimum set of outcomes that should be measured and reported in all clinical trials 
of a specific disease or trial population.5 The core outcome domains suggested by the HOME 
initiative are clinical signs, symptoms, long-term control of flares and quality of life (QoL).6-8 
Following the HOME roadmap,9 we performed a systematic review of the measurement properties of 
all instruments that were developed and validated to measure QoL in infants, children and 
adolescents with eczema. For adults, this step has already been completed.10  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Material and Methods 
Protocol and registration 
This systematic review was developed in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement.11 A completed PRISMA checklist is 
available as an online appendix to this publication. The study protocol was published12 and registered 
in the International Prospective Register of Systematic Reviews (PROSPERO): CRD42015023483. 
Literature search 
A systematic literature search in PubMed and EMBASE was conducted on 18 June 2015. The entire 
search strategy is shown in detail in the study protocol.12 Hand searching the PROQOLID database 
(http://www.proqolid.org) and reference lists of included studies and key articles on QoL in infants, 
children and adolescents with eczema complemented the systematic search. 
Eligible studies 
We applied the eligibility criteria presented in the protocol.12 Briefly, the study population of eligible 
development and validation studies of dermatology- or eczema-specific QoL instruments had to 
consist of at least 50% eczema patients younger than 16 years of age, or studies had to present 
subgroup analyses for this patient group. 
Content comparison 
The content of the included instruments was compared at the content domain level based on 
information from the original development paper. 
Assessment of the methodological quality of included studies 
We used the COnsensus-based Standards for the selection of health Measurement INstruments 
(COSMIN) checklist to judge the methodological quality of the included studies (www.cosmin.nl).13-16 
This checklist consists of 5 to 18 items per measurement property covering methodological 
standards; the compliance with these standards is rated on a four-point rating scale (that is, ‘poor,’ 
‘fair,’ ‘good,’ ‘excellent’). The lowest rating for any item pertaining to a certain measurement 
property determines the overall rating for this measurement property. 
Assessment of measurement properties and further characteristics of QoL 
instruments 
With the exception of criterion validity, all measurement properties from the COSMIN checklist were 
evaluated in this systematic review. Where available, interpretability and feasibility data were 
collected. Because we view them as distinct instruments, different language versions of the same 
questionnaire were considered separately throughout this review except for content comparison and 
instrument characteristics. 
Assessment of the adequacy of the measurement properties 
To evaluate the adequacy of the investigated measurement properties, we applied the 
corresponding predefined criteria recommended by the COSMIN group in a slightly modified version 
(Table 1).17 The specific changes we made to these criteria are explained in the protocol.12 Where 
studies used item response theory (IRT) methods in the assessment of measurement properties 
instead of the development of measurement instruments, we assessed the adequacy and 
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methodological quality of internal consistency, construct validity, structural validity, and cross-
cultural validity. 
Best evidence synthesis 
Findings on the same instrument from multiple studies were synthesized if the characteristics of the 
included studies were sufficiently similar, the results did not show considerably different or 
conflicting findings and the methodological quality of the included studies was adequate.18 Criteria 
for best evidence synthesis are found in Table 2. 
Generating recommendations for the use of QoL measurement instruments 
for eczema 
Depending on the adequacy of each instrument and the methodological quality of the included 
studies, a standardized recommendation for usage and necessary future validation work was made 
for each investigated instrument. 
Four categories of recommendation were made:12 
A. QoL measurement instrument meets all requirements and is recommended for use. 
B. QoL measure meets two or more adequacy criteria, but performance in all other required 
adequacy criteria is unclear, so that the outcome measure has the potential to be 
recommended in the future depending on the results of further validation studies. 
C. QoL measure has low adequacy in at least one required adequacy criterion (≥1 rating of 
‘minus’) and therefore is not recommended to be used any more. 
D. QoL measure has (almost) not been validated. Its performance in all or most relevant 
adequacy criteria is unclear so that it is not recommended to be used until further validation 
studies clarify its adequacy. 
 
Finally, we aimed to identify one best (currently available) instrument to assess QoL in infants, one 
best (currently available) instrument to assess QoL in children, and one best (currently available) 
instrument to assess QoL in adolescents with eczema. 
Results 
17 articles were included (Fig. 1).19-35 One paper complying with the inclusion criteria presented only 
summary information, making analyses of the evaluated questionnaires and measurement properties 
impossible; the paper was consequently excluded.36 Another paper containing data on the content 
validity of the Childhood Impact of Atopic Dermatitis (CIAD) did not formally meet inclusion criteria 
and was thus excluded.37 However, read in conjunction with the eligible development article of the 
CIAD,32 information on content validity could be extracted from that excluded paper and was 
therefore considered for this review.  
Most included studies reported on the Children’s Dermatology Life Quality Index (CDLQI, n=6)20,27-
29,31,34 and the Infants’ Dermatitis Quality of Life Index (IDQoL, n=6).19,22,23,27,30,35 Three studies 
evaluated the Childhood Atopic Dermatitis Impact Scale (CADIS)24,25,33 and two studies assessed the 
DISABKIDS Atopic Dermatitis Module (DISABKIDS-ADM).21,26 Information on the CIAD was available 
from two studies,32,37 but only one of them met the inclusion criteria.32 
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A comparison of the content covered by these five instruments is presented in Table 3. The CDLQI 
and the IDQoL are the most similar in content out of the five instruments. Table 4 shows other 
general characteristics of the included instruments. The CADIS, CIAD and IDQoL are proxy-reported, 
whereas the CDLQI is completed by children themselves. The questionnaire DISABKIDS-ADM is 
available both in a self- and a proxy-reported version. Only the CDLQI is a dermatology-specific 
instrument, all others are eczema-specific. The lowest number of items in a questionnaire is 7, the 
highest 45. Four of the five questionnaires apply a 4- or 5-point Likert scale; only the CIAD uses a 
dichotomous response format. 
Characteristics of the included studies 
An overview of settings and study populations in the included studies is shown in Table 5. Most 
studies were conducted in secondary/tertiary care settings in Europe. Sample sizes ranged from 8 to 
370 patients. 
Validity of the instruments and recommendations 
In total, we were able to rate the methodological quality of 84 measurement properties. Two 
measurement properties (2%) had good, 18 (21%) had fair and 64 (76%) had poor methodological 
quality. Detailed results for every instrument and study investigated in this systematic review can be 
found in the online appendix to this article (Tables S1-S80).  
Proxy-reported instruments 
Table 6 shows the number of studies assessing the different measurement properties of each 
included proxy-reported QoL instrument. The results of best evidence synthesis and the degree of 
recommendation for each proxy-reported instrument are found in Table 7. There was no instrument 
for which all relevant measurement properties have been investigated. Hence, there was also no 
instrument that fulfilled all pre-specified requirements of truth, discrimination and feasibility. 
With Cronbach’s α ranging from 0.76 to 0.93 for its subscales, internal consistency of the US version 
of the CADIS was found adequate.24 Most language versions of the CIAD demonstrated also good 
internal consistency, with Cronbach’s α values between 0.72 and 0.85.32 For the other instruments, 
internal consistency assessment was either done methodologically poorly or was not done at all. 
Measurement error was not investigated for any of the proxy-reported instruments included. Good 
reliability was shown for the US version of the CADIS, with Intraclass Correlation Coefficients (ICC) of 
0.89-0.95 for the domain scores and 0.96 for the total score between the two administrations.25 An 
ICC of 0.89 was found for the Dutch IDQoL, proving this instrument adequately reliable.35 While three 
language versions of the CIAD obtained an indeterminate rating for reliability, there was either no 
evidence or only evidence from methodologically poor studies for the other instruments. 
Data on content validity could be extracted for the US version of the CADIS, the UK version of the 
IDQoL and all language versions of the CIAD. However, all content validity assessments were done 
methodologically poorly. No clear rating could be assigned for the IRT methods used to investigate 
structural validity of the US version of the CIAD.32 Hypothesis testing was the measurement property 
most frequently evaluated, with information available for 14 of the 16 proxy-reported instruments. 
The two Italian CADIS versions correlated well with other QoL instruments; for instance, Spearman’s 
correlation coefficients of 0.74 with the IDQoL and 0.68 with the Dermatitis Family Impact were 
found for the long Italian CADIS.33 Discriminative validity of the US version of the CADIS was proven 
adequate since the instrument could differentiate patients according to severity as measured by 
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SCORing Atopic Dermatitis (SCORAD).25 Convergent validity of the UK version of the IDQoL was 
assessed in a study of fair methodological quality, but resulted in an indeterminate adequacy rating 
as only correlations with unrelated constructs were determined.30 Evidence on hypothesis testing for 
the remaining questionnaires was available from methodologically poor studies only.19,22,26,27,32,35 
Likewise, we could not draw a conclusion on cross-cultural validity, which was assessed for the long 
version of the Italian CADIS and four language versions of the CIAD, due to poor methodological 
study quality.32,33 
Responsiveness in eczema patients was investigated for only three questionnaires, but these 
assessments were of poor methodological quality.23,25,30,32 
Values for the minimal important change (MIC), the minimal important difference (MID) or validated 
banding systems are not available for the IDQoL.38 Evidence from several included validation studies 
suggests that the IDQoL does not exhibit floor and ceiling effects (i.e. ≥15% of patients having the 
lowest/highest possible score).22,27,30,35 We could not find information on the interpretability of the 
other proxy-reported questionnaires. Completion time of the CADIS amounted to approximately 6 
minutes in one study.24        
 
Self-reported instruments 
Table 8 shows the number of studies assessing the different measurement properties of each 
included self-reported QoL instrument. The results of best evidence synthesis and the degree of 
recommendation for each self-reported instrument are found in Table 9. There was no instrument 
for which all relevant measurement properties have been investigated. Hence, there was also no 
instrument that fulfilled all pre-specified requirements of truth, discrimination and feasibility. 
Internal consistency assessments were available for four included self-reported QoL instruments, but 
all were conducted methodologically poorly. Measurement error was not evaluated for any self-
reported instrument included. Both the Malay and the Mexican Spanish CDLQI were assigned an 
indeterminate rating for reliability, whereas this measurement property was not investigated for any 
other included self-reported instrument. 
Content validity was only investigated for the unknown language version of the DISABKIDS-ADM, but 
the methodological study quality was poor.21 Information on structural validity of the included self-
reported instruments was not available. Data on hypothesis testing was available for all instruments 
except the unknown language version of the DISABKIDS-ADM. We found an intermediate rating for 
discriminative validity of the Swedish CDLQI because the instrument was able to differentiate 
patients according to age, but could not distinguish patients with eczema only from patients with 
eczema and another allergic comorbidity.27 The assessments of construct validity of all other 
questionnaires were of poor methodological quality. Cross-cultural validity was not assessed for any 
self-reported QoL instrument included. 
An investigation of responsiveness was available for the Danish CDLQI only, but was done 
methodologically poorly.28 
Little information on interpretability is available for the self-reported QoL instruments. No floor and 
ceiling effects were found for the CDLQI in an analysis of 50 Swedish children with eczema.27 
Similarly, the CDLQI showed no floor and ceiling effects in the 47 children participating in its 
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development study.29 A recent meta-analysis provides an overview of CDLQI scores in different 
conditions, enabling comparisons of eczema patients’ scores with those of patients suffering from 
other diseases and helping to interpret patients’ CDLQI scores.39 Values for the MIC/MID for the 
CDLQI in eczema patients, as well as interpretability data for the DISABKIDS-ADM, could not be 
found.   
Discussion 
This systematic review assessed the measurement properties of five different QoL instruments for 
use in infants, children and adolescents with eczema. None of these instruments complied with all 
pre-specified filter criteria of truth, discrimination and feasibility, clearly indicating that more 
validation work is required. 
Strength and limitations of this review 
Strengths of this systematic review include a registered and published protocol, the application of a 
validated, precise search filter40 and of predefined eligibility criteria, and the use of the COSMIN 
checklist13-16 to judge the methodological quality of included studies. Every step of the review process 
was carried out by at least two reviewers. Furthermore, one reviewer (DH) was involved in every step 
of the review to ensure consistency across the participating reviewers. Discrepancies were resolved 
by frequent discussions within the whole team. 
A limitation of this review is the fact that only PubMed and EMBASE were searched. A thorough hand 
search of reference lists of included studies, important reviews and the PROQOLID database 
retrieved ten articles of interest not found in our initial systematic search, three of which were 
judged eligible and included. Another limitation may be that we could not consider responsiveness 
results of the CIAD obtained in the whole European sample because the paper provided no 
corresponding country-specific data. Also, information on discriminative validity of the CIAD could 
not be considered because the specific p values were not presented by McKenna et al.32 
Discussion of the results in light of other research 
Of all instruments reviewed, only the US version of the CADIS24 reached category B, hence having the 
potential to be recommended in the future depending on the results of further validation studies. All 
other questionnaires were placed in category D; their future use cannot be endorsed until further 
validation data is available.  
The CADIS, intended for use in eczema patients 0-6 years of age, is an internally consistent, reliable 
questionnaire with adequate construct validity. Its conceptual framework is based on a literature 
review and directed focus sessions with experts and parents. Compared to the other included 
instruments, the CADIS is unique in that it assesses both the QoL of the affected infant or child and 
the QoL of their parents. Although the instrument provides a total score, separate scores for the 
domains relating to the child’s QoL can also be calculated. Results from both the infant- or child-
related domains and the parent-related domains were considered for this systematic review. The 45-
item questionnaire was quickly completed. A disadvantage of the CADIS is that only three validated 
language versions of the instrument are currently available, with a validation study of a Spanish 
version being prepared for publication.41 The validation article of the Japanese CADIS version, still in 
press and recently published online,42 was not investigated in this systematic review because it had 
not yet been available when our systematic review was conducted. It will be taken into account in 
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the first update to this systematic review. Measurement error and structural validity of the CADIS 
have not yet been investigated. Moreover, future studies of improved methodological quality should 
look at content validity, cross-cultural validity, responsiveness and interpretability of the CADIS.  
The major finding of this systematic review is that nearly all existing QoL instruments for infants, 
children and adolescents with eczema are lacking significant validation data and were hence 
classified in category D. One reason for this is that 76% of the measurement properties were 
investigated in a methodologically poor manner, as compared to 25% in our preceding systematic 
review assessing the measurement properties of adult eczema QoL instruments.10 Part of this 
difference can be attributed to a stricter approach in judging whether hypotheses were formulated a 
priori when assessing hypothesis testing and responsiveness (item 4 in COSMIN box F, item 8 in 
COSMIN box I) in this review compared to the afore-mentioned review of adult eczema QoL 
instruments. However, only 16 of the 32 COSMIN boxes of hypothesis testing and responsiveness 
rated as ‘poor’ in this systematic review would obtain a better COSMIN rating if a less strict approach 
concerning hypotheses formulation was applied, still leaving 57% methodologically poorly 
investigated measurement properties in total. This result suggests that the methodological study 
quality is indeed worse than in the previous review on adult eczema QoL instruments.  
In addition to insufficient or methodologically poor validation of most instruments included, 
interpretability data is also lacking. A MID of 2.5 points on the CDLQI has been found in psoriasis 
patients,43 but corresponding data for eczema patients do not exist. Similarly, a banding system to 
help interpreting CDLQI scores has been developed,44 but the study did not meet our eligibility 
criteria because it reported on general dermatology patients in abstract form only. Interpretability in 
eczema patients is an important topic future validation studies should address. 
Only two of the five included instruments are self-reported by the affected children. While proxy-
reported measures, including the CADIS, may be particularly useful in infants and younger children, 
they are not suitable for older children and adolescents. As both the CDLQI and the DISABKIDS-ADM 
were placed in category D, there is currently no self-reported QoL instrument for paediatric eczema 
that can be recommended for use. CDLQI and DISABKIDS-ADM are also intended for use in 
adolescents. However, it has been argued that factors influencing adolescents’ QoL are 
fundamentally different from those observed in children and adults, leading to the development of 
the adolescent-specific Skindex-Teen.45 The development study of this questionnaire was not eligible 
for this review, though. Future validation studies of self-reported QoL instruments should therefore 
investigate whether they are suitable for adolescents with eczema as well, or if separate instruments 
for this age group are needed. 
Recommendations to researchers, clinicians and decision makers 
Currently only the CADIS has the potential to be recommended for use depending on the results of 
further validation studies. These validation studies should include all existing language versions of 
the CADIS and specifically examine measurement error, content validity, structural validity, cross-
cultural validity, responsiveness and interpretability. If these studies find favourable measurement 
properties of the CADIS, it should be translated and validated in more languages to increase 
international applicability. As the IDQoL is the QoL instrument most often used in eczema trials 
involving infants,46 it seems also advisable to undertake further validation work for this 
questionnaire. Additionally, future validation research should focus on self-reported QoL instruments 
for children and adolescents with eczema included in this review (CDLQI and DISABKIDS-ADM). For 
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the time being, since none of the investigated QoL instruments can be highly recommended, we 
suggest using the proxy-reported CADIS for infants and younger children with eczema, until formal 
consensus is reached by the HOME initiative. For older children and adolescents with eczema, there 
is currently no valid, reliable and feasible self-reported instrument. Trials in this age group should 
include the QoL instrument that in their authors’ opinion is best suited for children and adolescents 
with eczema. In older adolescents, the two QoL instruments for adults with eczema placed in 
category B in a previous systematic review,10 the Quality of Life Index for Atopic Dermatitis 
(QoLIAD)47 and the Dermatology Life Quality Index (DLQI),48 may be applicable.     
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Tables 
Table 4: Characteristics of the different instruments. 
Characteristic CADIS CDLQI CIAD DISABKIDS-ADM IDQoL 
Target 
population 
Children with 
eczema aged 0-
6 years (and 
their parents) 
Children with 
skin disease 
aged 4-16 years 
Children with 
eczema 
Children and 
adolescents 
with eczema 
Infants with 
eczema aged 
under 4 years 
Mode of 
administration Proxy-reported
a Self-reportedb Proxy-reporteda Self- or proxy-reportedb Proxy-reported
a 
Number of 
items 45/41/33* 10 9/7† 12 10 
Number of 
subscales 5 6 ND 2 8 
Number/type of 
response 
categories 
5-point Likert 
scale 
4-point Likert 
scale 
Dichotomous 
(true/not true) 
5-point Likert 
scale (and ‘not 
applicable’) 
4-point Likert 
scale 
Scoring 
algorithm 
Calculation of 
domain scores 
by summing up 
item scores of 
all items in one 
domain; 
calculation of a 
total score by 
summing up 
scores of all 
items in the 
questionnaire 
Calculation of a 
sum score, 
range 0-30 
ND 
Calculation of a 
mean 
standardized 
score for each 
dimension, 
range 0-100 
Calculation of a 
sum score, 
range 0-30 
Recall period in 
the items 4 weeks 1 week 
None (‘at the 
moment’) ND 1 week 
Administration 
costs 
No 
administration 
costs41 
No charge for 
non-funded 
studies; $11.50 
per patient for 
pharmaceutical 
companies51 
ND ND 
No charge for 
use in non-
funded studies 
and routine 
clinical practice; 
$11.50 per 
patient for 
pharmaceutical 
companies52 
Available 
translations 
English (US), 
Italian, 
Japanese41 
More than 5051 
Dutch, English 
(UK), English 
(US), French, 
German 
Brazilian 
Portuguese, 
other 
languages‡ 
More than 2052 
a ’Proxy-reported’ means that the (primary) caregiver of an infant fills in a questionnaire that assesses the quality of life of the infant. 
Proxy-reported instruments are often used in infants and younger children because they cannot report on their quality of life themselves 
due to their inability to read and a lack of understanding. 
b ‘Self-reported’ instruments are used in older children and adolescents. These questionnaires are filled in by the children/adolescents 
themselves, not by their caregiver. 
*45 items in the original version, 41 items in the long Italian version, 33 items in the short Italian version (Italian versions include fewer 
items as some were found to misfit in factor analysis). 
†9 items in the Dutch, English (UK), French and German version each; 7 items in the English (US) version. The European versions and the US 
questionnaire have 6 items in common (of these, 3 are used as link items). 
‡Not described which language versions were tested in the European validation study. 
Abbreviations: CADIS, Childhood Atopic Dermatitis Impact Scale; CDLQI, Children’s Dermatology Life Quality Index; CIAD, Childhood Impact 
of Atopic Dermatitis; DISABKIDS-ADM, DISABKIDS Atopic Dermatitis Module; IDQoL, Infants’ Dermatitis Quality of Life Index; ND, not 
described; UK, United Kingdom; US, United States (of America). 
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Table 5: Important characteristics of the included development and validation studies. 
  Study characteristics 
     Study population 
QoL 
instrument 
Number 
of 
studies 
Geographic 
location(s) Language(s) Setting(s) 
Number of 
participants per 
study 
Age range 
English 
CADIS (US) 2
24,25 
United 
States of 
America 
English (US) Secondary/tertiary care 270 1.5-71.4 mos 
Italian 
CADIS (long 
version) 
133 Italy Italian Secondary/tertiary care 135 2-72 mos 
Italian 
CADIS 
(short 
version) 
133 Italy Italian Secondary/tertiary care 135 2-72 mos 
Danish 
CDLQI 1
28 Denmark Danish Secondary/tertiary care 35 ND 
English 
CDLQI (UK) 1
29 United Kingdom English (UK) 
Secondary/tertiary 
care 47 
ND 
(mean±SD: 
9.2±3.6 yrs) 
Malay 
CDLQI 1
20 Malaysia Bahasa Malaysia 
Secondary/tertiary 
care 33 
ND 
(youngest: 7 
yrs) 
Serbian 
CDLQI 1
31 Serbia Serbian Secondary/tertiary care 64 4-16 yrs 
Spanish 
CDLQI 
(Mexico) 
134 Mexico Mexican Spanish 
Secondary/tertiary 
care 64 8-16 yrs 
Swedish 
CDLQI 1
27 Sweden Swedish Secondary/tertiary care 50 5-15 yrs 
Dutch CIAD 132,37* Netherlands Dutch 
Secondary/tertiary 
care and 
community37 
15 (item 
generation)37 ND
37 
20 (field 
testing)37 ND
37 
Clinical trial32† 4832 ND32 
English 
CIAD (UK) 1
32,37* United Kingdom English (UK) 
Secondary/tertiary 
care and 
community37 
35 (item 
generation)37 ND
37 
20 (field 
testing)37 ND
37 
Clinical trial32† 2132 ND32 
English 
CIAD (US) 1
32,37* 
United 
States of 
America 
English (US) 
Secondary/tertiary 
care and 
community37 
2037 ND37 
Clinical trial32† 24332 
ND 
(mean±SD: 
48±21.6 
mos)32 
French 
CIAD 1
32,37* France French 
Secondary/tertiary 
care and 
community37 
1937 ND37 
Clinical trial32† 5232 ND32 
German 
CIAD 1
32,37* Germany German 
Secondary/tertiary 
care and 
community37 
1937 ND37 
Clinical trial32† 8732 ND32 
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Italian CIAD 137* Italy Italian 
Secondary/tertiary 
care and 
community 
15 (item 
generation) ND 
8 (field testing) ND 
Spanish 
CIAD 1
37* Spain Spanish 
Secondary/tertiary 
care and 
community 
20 ND 
DISABKIDS-
ADM 
(unknown 
language) 
121 
ND (2 
European 
countries) 
ND ND 29 ND 
Portuguese 
DISABKIDS-
ADM 
(Brazil, 
proxy-
reported 
version) 
126 Brazil Brazilian Portuguese 
Secondary/tertiary 
care 52 8-18 yrs 
Portuguese 
DISABKIDS-
ADM 
(Brazil, self-
reported 
version) 
126 Brazil Brazilian Portuguese 
Secondary/tertiary 
care 52 8-18 yrs 
Arabic 
IDQoL 1
19 Saudi Arabia Arabic Secondary/tertiary care 370 
ND 
(mean±SD: 
8.8±9.9 mos) 
Dutch 
IDQoL 1
35 Netherlands Dutch Primary care 66 0.5-83.5 mos 
English 
IDQoL (UK) 2
23,30 United Kingdom English (UK) 
Secondary/tertiary 
care23 203
23 1-53 mos23 
Secondary/tertiary 
care and 
community30 
89 (validation)30 ND (mean: 20.16 mos)30 
Secondary/tertiary 
care30 
92 
(development)30 ND
30 
Italian 
IDQoL 1
22 Italy Italian Secondary/tertiary care 21 12-48 mos 
Swedish 
IDQoL 1
27 Sweden Swedish Secondary/tertiary care 28 24-48 mos 
Abbreviations: CADIS, Childhood Atopic Dermatitis Impact Scale; CDLQI, Children’s Dermatology Life Quality Index; CIAD, Childhood Impact 
of Atopic Dermatitis; DISABKIDS-ADM, DISABKIDS Atopic Dermatitis Module; IDQoL, Infants’ Dermatitis Quality of Life Index; mos, months; 
ND, not described; QoL, quality of life; SD, standard deviation; UK, United Kingdom; US, United States (of America); yrs, years. 
 
*The study by McKenna et al. from 2005 did not formally meet the inclusion criteria. However, read in conjunction with the eligible 2007 
CIAD development article by McKenna et al., information on content validity of the CIAD could be extracted from the 2005 article. As a 
result, only the article by McKenna et al. from 2007 was formally included, but information from the 2005 article was also taken in 
consideration for content validity assessment. 
†These studies were conducted in the context of a clinical trial. No further information on the participating health service providers was 
presented, which is why it was not possible to group these study populations in one of the three categories community, primary care, or 
secondary/tertiary care. 
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Table 7: Summary of measurement properties of proxy-reported QoL instruments for 
infants, children and adolescents with eczema. 
Measure
ment 
property 
Engl
ish 
CAD
IS 
(US) 
Itali
an 
CAD
IS 
(lon
g 
versi
on) 
Itali
an 
CAD
IS 
(sho
rt 
versi
on) 
Du
tch 
CIA
D 
Engl
ish 
CIA
D 
(UK
) 
Engli
sh 
CIAD 
(US) 
Fren
ch 
CIAD 
Ger
man 
CIAD 
Ital
ian 
CIA
D 
Spa
nish 
CIA
D 
Portug
uese 
DISAB
KIDS-
ADM 
(Brazil, 
proxy-
report
ed 
versio
n) 
Ara
bic 
IDQ
oL 
Dut
ch 
ID
Qo
L 
Engli
sh 
IDQ
oL 
(UK) 
Ital
ian 
IDQ
oL 
Swe
dish 
IDQ
oL 
Internal 
consistenc
y 
+ Weak 
Wea
k + 
We
ak + + + / / Weak 
We
ak / / 
We
ak / 
Measurem
ent error / / / / / / / / / / / / / / / / 
Reliability + Weak 
Wea
k 
We
ak 
We
ak 
? 
(limi
ted) 
? 
(limi
ted) 
? 
(limi
ted) 
/ / / / + Weak 
We
ak / 
Content 
validity 
We
ak / / 
We
ak 
We
ak 
Wea
k 
Wea
k 
Wea
k 
We
ak 
Wea
k / / / 
Wea
k / / 
Structural 
validity / 
Wea
k / / / 
? 
(limi
ted) 
/ / / / / / / / / / 
Hypothesi
s testing + + + 
We
ak 
We
ak 
Wea
k 
Wea
k 
Wea
k / / Weak 
We
ak 
We
ak 
? 
(limi
ted) 
We
ak 
Wea
k 
Cross-
cultural 
validity 
/ Weak / 
We
ak 
We
ak / 
Wea
k 
Wea
k / / / / / / / / 
Responsiv
eness 
We
ak / / / / 
Wea
k / / / / / / / 
Wea
k / / 
Recomme
ndation B D D D D D D D D D D D D D D D 
Abbreviations: CADIS, Childhood Atopic Dermatitis Impact Scale; CIAD, Childhood Impact of Atopic Dermatitis; DISABKIDS-ADM, DISABKIDS 
Atopic Dermatitis Module; IDQoL, Infants’ Dermatitis Quality of Life Index; QoL, quality of life; UK, United Kingdom; US, United States (of 
America). 
Recommendations are defined as follows: A, QoL measurement instrument meets all requirements and is recommended for use; B, QoL 
measure meets two or more adequacy items, but performance in all other required adequacy items is unclear, so that the outcome 
measure has the potential to be recommended in the future depending on the results of further validation studies; C, QoL measure has low 
adequacy in at least one required adequacy criterion (≥1 rating of ‘minus’) and therefore is not recommended to be used any more; D, QoL 
measure has (almost) not been validated. Its performance in all or most relevant adequacy items is unclear so that it is not recommended 
to be used until further validation studies clarify its adequacy. 
+, positive rating indicating adequate measurement property; ? (limited), intermediate rating indicating intermediate measurement 
property; Weak, measurement property was assessed only in studies of poor methodological quality (please refer to Table 2 for further 
details); / = not assessed. 
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Table 9: Summary of measurement properties of self-reported QoL instruments for infants, 
children and adolescents with eczema. 
Measurement 
property 
Danish 
CDLQI 
English 
CDLQI 
(UK) 
Malay 
CDLQI 
Serbian 
CDLQI 
Spanish 
CDLQI 
(Mexico) 
Swedish 
CDLQI 
DISABKIDS-
ADM 
(unknown 
language) 
Portuguese 
DISABKIDS-ADM 
(Brazil, self-
reported version) 
Internal consistency / / Weak Weak Weak / / Weak 
Measurement error / / / / / / / / 
Reliability / / ? (limited) / ? (limited) / / / 
Content validity / / / / / / Weak / 
Structural validity / / / / / / / / 
Hypothesis testing Weak Weak Weak Weak Weak ? (limited) / Weak 
Cross-cultural validity / / / / / / / / 
Responsiveness Weak / / / / / / / 
Recommendation D D D D D D D D 
Abbreviations: CDLQI, Children’s Dermatology Life Quality Index; DISABKIDS-ADM, DISABKIDS Atopic Dermatitis Module; QoL, quality of 
life; UK, United Kingdom; US, United States (of America). 
Recommendations are defined as follows: A, QoL measurement instrument meets all requirements and is recommended for use; B, QoL 
measure meets two or more adequacy items, but performance in all other required adequacy items is unclear, so that the outcome 
measure has the potential to be recommended in the future depending on the results of further validation studies; C, QoL measure has low 
adequacy in at least one required adequacy criterion (≥1 rating of ‘minus’) and therefore is not recommended to be used any more; D, QoL 
measure has (almost) not been validated. Its performance in all or most relevant adequacy items is unclear so that it is not recommended 
to be used until further validation studies clarify its adequacy. 
? (limited), intermediate rating indicating intermediate measurement property; +/-, conflicting findings; Weak, measurement property was 
assessed only in studies of poor methodological quality (please refer to Table 2 for further details); / = not assessed. 
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